GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kolon TissueGene Inc (XKRX:950160) » Definitions » Scaled Net Operating Assets

Kolon TissueGene (XKRX:950160) Scaled Net Operating Assets : 0.75 (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kolon TissueGene Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Kolon TissueGene's operating assets for the quarter that ended in Sep. 2024 was ₩164,149 Mil. Kolon TissueGene's operating liabilities for the quarter that ended in Sep. 2024 was ₩27,131 Mil. Kolon TissueGene's Total Assets for the quarter that ended in Jun. 2024 was ₩183,595 Mil. Therefore, Kolon TissueGene's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.75.


Kolon TissueGene Scaled Net Operating Assets Historical Data

The historical data trend for Kolon TissueGene's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon TissueGene Scaled Net Operating Assets Chart

Kolon TissueGene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial 0.06 0.06 0.09 0.66 0.86

Kolon TissueGene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.64 0.82 0.95 0.75

Competitive Comparison of Kolon TissueGene's Scaled Net Operating Assets

For the Biotechnology subindustry, Kolon TissueGene's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kolon TissueGene's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kolon TissueGene's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Kolon TissueGene's Scaled Net Operating Assets falls into.



Kolon TissueGene Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Kolon TissueGene's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(107477.854-13471.466)/109889.896
=0.86

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=134910.381 - 27432.527
=107477.854

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=19947.001 - 5567.897 - 907.638
=13471.466

Kolon TissueGene's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(164149.101-27131.249)/183595.156
=0.75

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=192872.644 - 28723.543
=164149.101

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=44004.341 - 4978.423 - 11894.669
=27131.249

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon TissueGene Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Kolon TissueGene's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Kolon TissueGene Business Description

Traded in Other Exchanges
N/A
Address
9713 Key West Avenue, Suite 300, Rockville, MD, USA, 20850
Kolon TissueGene Inc is a biopharmaceutical company that develops regenerative therapies for the treatment of various orthopedic disorders. It is developing four product candidates, TG-C, TG-B, TG-D and TG-N for regeneration of cartilage, bone, disc and nerve.

Kolon TissueGene Headlines

No Headlines